Florence DALENC

Prof. Florence DALENC


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2019 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
PJPascal Jézéquel
Pascal Jézéquel
OKOlivier Kerdraon
Olivier Kerdraon
Hubert HondermarckHubert Hondermarck
Hubert Hondermarck
CGCatherine Guérin-Charbonnel
Catherine Guérin-Charbonnel
HLHamza Lasla
Hamza Lasla
MCMario Campone
Mario Campone
Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment of triple-negative breast cancer (TNBC), and therefore, molecular subtyping and identification of therapeutic pathways are required to optimize medical care. The aim of the present study was to define robust TNBC subtypes with clinical relevance. Gene expression profiling by means of DNA chips was conducted in an internal TNBC cohort composed of 238 patients. In addition, external data (n = 257), obtained by using the same DNA chip, were used for validation. Fuzzy clustering was followed by functional annotation of the clusters. Immunohistochemistry was used to confirm transcriptomics results: CD138 and CD20 were used to test for plasma cell and B lymphocyte infiltrations, respectively; MECA79 and CD31 for tertiary lymphoid structures; and UCHL1/PGP9.5 and S100 for neurogenesis. We identified three molecular clusters within TNBC: one molecular apocrine (C1) and two basal-like-enriched (C2 and C3). C2 presented pro-tumorigenic immune response (immune suppressive), high neurogenesis (nerve infiltration), and high biological aggressiveness. In contrast, C3 exhibited adaptive immune response associated with complete B cell differentiation that occurs in tertiary lymphoid structures, and immune checkpoint upregulation. External cohort subtyping by means of the same approach proved the robustness of these results. Furthermore, plasma cell and B lymphocyte infiltrates, tertiary lymphoid structures, and neurogenesis were validated at the protein levels by means of histological evaluation and immunohistochemistry. Our work showed that TNBC can be subcategorized in three different subtypes characterized by marked biological features, some of which could be targeted by specific therapies.

11 December 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
EPElvire Pons-Tostivint
Elvire Pons-Tostivint
YKYoulia Kirova
Youlia Kirova
ALAmélie Lusque
Amélie Lusque
MCMario Campone
Mario Campone
JGJulien Geffrelot
Julien Geffrelot
FDFlorence DALENC
Florence DALENC

1 August 2020 in The Breast
Verified
Journal Article
Open access
SFSophie Frank
Sophie Frank
MCMatthieu Carton
Matthieu Carton
CDCoraline Dubot
Coraline Dubot
MCMario Campone
Mario Campone
BPBarbara Pistilli
Barbara Pistilli
PCPaul Cottu
Paul Cottu
Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups ( 60 years(y)). ESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014. Among 14 403 women included, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were 60 y respectively. Pts 60y) and triple negative subtypes (27.4 vs 14.6% in >60y), and more frequent visceral involvement (36.3 vs 29.8% in >60y). At a median follow-up of 48 months, median OS differed across age groups: 38.8, 38.4 and 35.6 months for pts 60y, respectively (p < 0.0001). Compared to pts <40y, older pts had a statistically significant higher risk of death (all causes of death included), although of limited clinical value (HR = 1.1, IC 95%:1.01-1.20). There was a significant trend for better OS in pts <40y with HER2+ and luminal diseases. A possible explanation is a greater use of anti-Her2 therapies as first-line treatments: 86.6, 81.9 and 74.9% for pts 60y, respectively (p < 0.0001). Although young age seems associated with more aggressive presentations at diagnosis of MBC, it has no deleterious effect on OS in this large series.

22 August 2017 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
FDFlorence DALENC
Florence DALENC
VRV. Ribet
V. Ribet
ARA.B. Rossi
A.B. Rossi
JGJ. Guyonnaud
J. Guyonnaud
CBC. Bernard-Marty
C. Bernard-Marty
VSV. Sibaud
V. Sibaud

8 October 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MDMélodie Dell’ova
Mélodie Dell’ova
EMEléonora De Maio
Eléonora De Maio
SGSéverine GUIU
Séverine GUIU
LRLise Roca
Lise Roca
FDFlorence DALENC
Florence DALENC
SPStéphane Pouderoux
Stéphane Pouderoux
Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. Clinical and biological assessment of toxicity was performed at each visit. Tumour response was assessed every 3 cycles of treatment. A database was created to collect clinical, pathological and treatment data. Two hundred and fifty-eight patients were included in the study. Median age was 59 years old. Tumours were Hormone Receptor (HR)-positive (73.3 %) HER2-positive (10.2 %), and triple negative (TN, 22.5 %). 86.4 % of the patients presented with visceral metastases, mainly in the liver (67.4 %). Median previous metastatic chemotherapies number was 4 [1–9]. Previous treatments included anthracyclines and/or taxanes (100 %) and capecitabine (90.7 %). Median number of EM cycles was 5 [1–19]. The relative dose intensity was 0.917. At the time of analysis (median follow-up of 13.9 months), 42.3 % of the patients were still alive. The objective response rate was 25.2 % (95 %CI: 20–31) with a 36.1 % clinical benefit rate (CBR). Median time to progression (TTP) and overall survival were 3.97 (95 %CI: 3.25–4.3) and 11.2 (95 %CI: 9.3–12.1) months, respectively. One- and 2-year survival rates were 45.5 and 8.5 %, respectively. In multivariate analysis, HER2 positivity (HR = 0.29), the presence of lung metastases (HR = 2.49) and primary taxanes resistance (HR = 2.36) were the only three independent CBR predictive factors, while HR positivity (HR = 0.67), the presence of lung metastases (HR = 1.52) and primary taxanes resistance (HR = 1.50) were the only three TTP independent prognostic factors. Treatment was globally well tolerated. Most common grade 3–4 toxicities were neutropenia (20.9 %), peripheral neuropathy (3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %) and thrombocytopenia (0.4 %). Thirteen patients (5 %) developed febrile neutropenia. EM is an effective new option in heavily pretreated MBC, with a favourable efficacy/safety ratio in a clinical practice setting. Our results comfort the use of this new molecule and pledge for the evaluation of EM-trastuzumab combination in this setting. Tumour biology, primary taxanes sensitivity and metastatic sites could represent useful predictive and prognostic factors.

11 July 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
William JacotWilliam Jacot
William Jacot
FDFlorence DALENC
Florence DALENC
ECEvelyne Crapez
Evelyne Crapez
LCLeonor Chaltiel
Leonor Chaltiel
ADAnna Durigova
Anna Durigova
Pierre-Jean LamyPierre-Jean Lamy
Pierre-Jean Lamy